Certain HPV16 antibodies may predict oropharyngeal cancer survival

the ONA take:

Certain human papillomavirus (HPV)-16 antibodies in the blood was associated with improved survival rates among patients with HPV-related oropharyngeal carcinoma, according to a new study.

For the study, researchers analyzed blood samples from 209 patients with previously untreated oropharyngeal carcinoma. Of those, 96 had confirmed HPV-positive disease. Samples were screened for HPV16 antibodies E1, E4-7, L1, L2, and the N-terminal and C-terminal fragments of E2.

Results showed that patients with any of the E antibodies had improved overall and progression-free survival versus those who tested negative for the antibodies. HPV-positive patients who tested positive for NE2, E1, or E6 antibodies also had a reduced mortality and disease progression risk.

Researchers found no survival advantage for people who tested positive for L antibodies.

Clinical trials are currently ongoing to evaluate whether vaccines can stimulate these antibodies to improve outcomes in patients with HPV-related cancers.

Certain HPV16 antibodies may predict oropharyngeal cancer survival
Certain HPV-16 antibodies in the blood associated with improved survival in HPV-related oropharyngeal carcinoma.
The presence of certain human papillomavirus (HPV)-16 antibodies in the blood was associated with improved rates of survival among patients with HPV-related oropharyngeal carcinoma
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs